News & Updates

Etrasimod shows promise in eosinophilic oesophagitis

In the treatment of eosinophilic oesophagitis, the use of etrasimod is well tolerated and results in sustained histological and endoscopic improvements and symptom reduction, according to the results of a phase II study.

Monitor kidney function to reduce CV risk in CKD patients: study

In patients with stable chronic kidney disease (CKD), the risk of cardiomyopathy caused by kidney disease appears to be greater than the risk of CKD progression due to heart disease, suggests a study, noting that these observational analyses do not establish causality.

High, increasing BMI ups risk of adulthood OSA

Individuals with high or continuously increasing BMI from childhood to middle age are at greater risk of developing obstructive sleep apnoea (OSA) later in life, reveals a study.

Why Combine? Addressing the Gap for Blood Pressure Control

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

Personalizing upfront treatment options for advanced EGFRm NSCLC

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

Dietary fibre intake protective against stroke, mortality

Consuming high amounts of dietary fibre helps reduce the risk of stroke and of all-cause mortality among individuals who have already survived a stroke, according to a study.

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

The glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) dual agonist HEC88473 demonstrates an acceptable safety profile and potential efficacy in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).